
WHAT IS CLAIMED IS:

1. Use of a combination of compounds in the manufacture of a medicament for treating a disease or condition, wherein the combination includes an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, and an effective amount of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:

the Compound (A) has the structure:




(A)


wherein:


R^1 is selected from the group consisting of hydrogen, halogen and a substituted or unsubstituted C_1-C_6 alkyl;

Ring A is selected from the group consisting of a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-6 membered monocyclic heteroaryl;

Ring B is selected from the group consisting of a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl and a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl;

R^2 is selected from the group consisting of 

, 

and 

;

m is 0, 1, 2 or 3;

R^3 is selected from the group consisting of halogen and a substituted or unsubstituted C_1-C_6 alkyl;

X is selected from the group consisting of hydrogen, halogen, hydroxy, cyano, a substituted or unsubstituted 4-6 membered monocyclic heterocyclyl, a substituted or unsubstituted amine(C_1-C_6 alkyl), a substituted or unsubstituted –NH-$(CH_2)_{1-6}$-amine, a mono-substituted amine, a di-substituted amine, an amino, a substituted or unsubstituted C_1-C_6 alkyl, a substituted or unsubstituted C_1-C_6 alkoxy, a substituted or unsubstituted C_3-C_6 cycloalkoxy, a substituted or

unsubstituted (C_1-C_6 alkyl)acyl, a substituted or unsubstituted C-amido, a substituted or unsubstituted N-amido, a substituted or unsubstituted C-carboxy, a substituted or unsubstituted O-carboxy, a substituted or unsubstituted O-carbamyl and a substituted or unsubstituted N-carbamyl;

Y is CH or N;

Y^1 is CR^{4A} or N;

Y^2 is CR^{4B} or N;


Ring C is selected from the group consisting of a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl, a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl and a substituted or unsubstituted 7-10 membered bicyclic heterocyclyl;

R^{4A} and R^{4B} are independently selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-4} alkyl; and


R^5 is a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl; and

the Compound (B) is a Bcl-2 inhibitor, or a pharmaceutically acceptable salt thereof;

wherein the Bcl-2 inhibitor is selected from the group consisting of


AGP-2575, AGP-1252, venetoclax (ABT-199) 


,

navitoclax (ABT-263) 

, S55746/BCL201, S65487, BGB-11417, FCN-338 and AZD0466, or a pharmaceutically acceptable salts of any of the foregoing;

wherein Compound (A), or a pharmaceutically acceptable salt thereof, and Compound (B), or a pharmaceutically acceptable salt thereof, are provided in a single pharmaceutical composition or separate pharmaceutical compositions.

2. The use of Claim 1, wherein the compound (A) is , or a pharmaceutically acceptable salt thereof.

3. The use of Claim 1, wherein the compound (A) is , or a pharmaceutically acceptable salt thereof.

4. The use of any one of Claims 1-3, wherein Compound (A), or a pharmaceutically acceptable salt thereof, is provided prior to Compound (B), or a pharmaceutically acceptable salt thereof.

5. The use of any one of Claims 1-3, wherein Compound (A), or a pharmaceutically acceptable salt thereof, is provided concomitantly with Compound (B), or a pharmaceutically acceptable salt thereof.

6. The use of any one of Claims 1-3, wherein Compound (A), or a pharmaceutically acceptable salt thereof, is provided subsequent to Compound (B), or a pharmaceutically acceptable salt thereof.

7. The use of any one of Claims 1-6, wherein the hematological malignancy is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).

8. The use of Claim 7, wherein the hematological malignancy is non-Hodgkin’s lymphoma.

9. The use of Claim 7, wherein the hematological malignancy is Multiple Myeloma and blastic plasmacytoid dendritic cell neoplasm.

10. The use of any one of Claims 1-6, wherein the disease or condition is a solid tumor.

11. The use of any one of Claims 1-6, wherein the disease or condition is selected from the group consisting of a bladder cancer, a brain cancer, a breast cancer, a cervical cancer, a choriocarcinoma, a cervicocerebral cancer, a colon cancer, an endometrial cancer, an esophageal cancer, a gallbladder/bile duct cancer, a head and neck cancer (including oral cancer), a hepatocellular cancer, a lung cancer, a non-small cell cancer, a mesothelioma, an ovarian cancer, an osteosarcoma, a pancreatic cancer, a penis cancer, an anal cancer, a prostate cancer, a testicular cancer, a small cell cancer, a small cell lung cancer, a stomach cancer, a rectal cancer, a renal pelvis/ureter cancer, a skin cancer, a soft tissue sarcoma, a stomach cancer, a testicular cancer, a thyroid cancer, an uterus body cancer, and an uterocervical cancer.